Blujepa is the first in a new class of oral antibiotics for uUTIs in nearly 30 years Over half of all women experience a uUTI in their lifetime, with approximately 30% suffering from a recurrent ...
The Food and Drug Administration has expanded the approval of Avycaz (ceftazidime and avibactam) to include pediatric patients aged ≥3 months for the treatment of complicated intra-abdominal ...
In very low birth weight (VLBW) infants, acute renal impairment (ARI) is common, but there is no consensus about criteria for its diagnosis. Neutrophil gelatinase-associated lipocalin (NGAL) is an ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, announced today that the U.S. Food and Drug Administration (FDA) approved OXLUMO™ ...
A new thulium fiber laser system may provide improved outcomes in the treatment of urinary stones for pediatric patients, compared to the current standard for laser lithotripsy, reports a study in The ...
Royal College of Physicians (1991) 1991–2000 Aggressive treatment, prophylaxis and investigation of all children aged <7 years [81] American Academy of Pediatrics Guideline (1999) Aggressive treatment ...
Dr. Kanika Bowen-Jallow, a board-certified pediatric surgeon at Cook Children’s Pediatric Surgery Center in Prosper, TX, is now the ninth Black female pediatric surgeon in the United States, according ...
ZERBAXA The approvals were based on data from pediatric trials evaluating treatment for complicated intra-abdominal infections and complicated urinary tract infections. The Food and Drug ...
– First RNAi Therapeutic Approved in U.S. for Use in Both Children and Adults, and Third RNAi Medicine to Receive FDA Approval in Less than Three Years – – Approval Based on Results from Both ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback